Positive data for Eylea in branch form of occlusion

Share this article:
On Monday Regeneron reported more positive data for its wet AMD/macular edema drug Eylea (aflibercept). This time, it's in patients with macular edema following branch retinal vein occlusion (BRVO), a potentially blinding retinal disorder caused by a blockage in the blood vessels branching from the main vein draining the retina.

The biotech, which said it intends to submit a regulatory application for marketing approval for a possible BRVO indication in the US within the next several months, added that the Phase III trial was the eighth positive one for Eylea.

Regeneron was already prepping an NDA submission for diabetic macula edema (DME), while its European marketing partner, Bayer, is on track to do the same abroad. Roche's wet AMD drug Lucentis already has DME on its label.

As FiercePharma pointed out, Eylea's two existing indications—wet AMD and for macular edema following central retinal vein occlusion (CRVO)—generated US revenue of $643.7 million in the first half of this year, with some of that going to ex-US marketing partner Bayer.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.